BRPI0419067A - método para aumento da cognição utilizando ziprasidona - Google Patents
método para aumento da cognição utilizando ziprasidonaInfo
- Publication number
- BRPI0419067A BRPI0419067A BRPI0419067-0A BRPI0419067A BRPI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- ziprasidone
- formula
- compound
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
MéTODO PARA AUMENTO DA COGNIçãO UTILIZANDO ZIPRASIDONA. A presente invenção, em um aspecto, refere-se a um método para utilização de compostos heterocíclicos de piperazinil, de fórmula I, tal como definida abaixo, para aumento da cognição em um mamífero, incluindo um ser humano, por exemplo um mamífero afetado com psicose, autismo, demência ou retardo mental, compreendendo a administração, ao mamífero, de uma quantidade eficaz de um composto de fórmula I (por exemplo, ziprasidona). Em um outro aspecto, a presente invenção é direcionada para um método de redução ou melhoria, em um mamífero, incluindo um ser humano, afetado com um distúrbio ou condição selecionado a partir de autismo, retardo mental, distúrbio obsessivo-compulsivo e demência, sintomas positivos (por exemplo, agressividade excessiva, comportamento sexual desinibido, comportamento sexual inadequado, agitação, comportamento compulsivo, tal como bater a cabeça, morder os lábios, auto-mutilação ou comportamento estereotipado) associados com os distúrbios ou condições acima referidos, método esse que compreende a administração, ao mamífero, de uma quantidade eficaz de um composto de fórmula I (por exemplo, ziprasidona). Em um outro aspecto, a presente invenção é direcionada para um método de tratamento do distúrbio bipolar pediátrico em um mamífero, incluindo um ser humano, método esse que compreende a administração, ao mamífero, de uma quantidade eficaz de um composto de fórmula I (por exemplo, ziprasidona). Os compostos do composto de fórmula I são definidos como se segue: ou um sal de adição de ácido farmaceuticamente aceitável do mesmo, em que Ar, n, X e Y são como definidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47137903P | 2003-05-16 | 2003-05-16 | |
PCT/IB2004/001600 WO2004100956A1 (en) | 2003-05-16 | 2004-05-05 | Method for enhancing cognition using ziprasidone |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0419067A true BRPI0419067A (pt) | 2007-12-11 |
Family
ID=33452442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0419067-0A BRPI0419067A (pt) | 2003-05-16 | 2004-05-05 | método para aumento da cognição utilizando ziprasidona |
Country Status (9)
Country | Link |
---|---|
US (2) | US20050014764A1 (pt) |
EP (1) | EP1626722A1 (pt) |
JP (1) | JP2006528236A (pt) |
AR (1) | AR044337A1 (pt) |
BR (1) | BRPI0419067A (pt) |
CA (2) | CA2625837A1 (pt) |
MX (1) | MXPA05012325A (pt) |
TW (1) | TW200507847A (pt) |
WO (1) | WO2004100956A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1408976B3 (en) | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
ATE388698T1 (de) | 2003-04-29 | 2008-03-15 | Orexigen Therapeutics Inc | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
MY145694A (en) * | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
US20100222353A1 (en) * | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
EP1988077A4 (en) * | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
WO2008046049A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
EP2073806B1 (en) * | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
WO2008046046A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
KR20090090316A (ko) | 2006-11-09 | 2009-08-25 | 오렉시젠 세러퓨틱스 인크. | 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법 |
CN103497114A (zh) * | 2007-06-29 | 2014-01-08 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
AU2009244082A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2010045197A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
RU2544852C2 (ru) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
KR20120124423A (ko) | 2010-01-11 | 2012-11-13 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
BR112012021086A2 (pt) | 2010-02-26 | 2016-05-17 | Xenon Pharmaceuticals Inc | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos |
JP2013526542A (ja) | 2010-05-12 | 2013-06-24 | アッヴィ・インコーポレイテッド | キナーゼのインダゾール阻害薬 |
PT3730132T (pt) | 2012-06-06 | 2022-08-16 | Nalpropion Pharmaceuticals Llc | Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
UA47467C2 (uk) * | 1996-05-07 | 2002-07-15 | Файзер Інк. | Тригідрат мезилату 5-(2-(4-(1,2-бензизотіазол-3-іл)-1-піперазиніл)етил)-6-хлор-1,3-дигідро-2(1н)-індол-2-ону (зипразидону), фармацевтична композиція та спосіб лікування психічних розладів |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
AU3329500A (en) * | 1999-03-30 | 2000-10-23 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
CA2363942A1 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
-
2004
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en active Application Filing
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR044337A1 (es) | 2005-09-07 |
MXPA05012325A (es) | 2006-01-30 |
JP2006528236A (ja) | 2006-12-14 |
US20080269246A1 (en) | 2008-10-30 |
CA2625837A1 (en) | 2004-11-25 |
US20050014764A1 (en) | 2005-01-20 |
CA2525323A1 (en) | 2004-11-25 |
EP1626722A1 (en) | 2006-02-22 |
TW200507847A (en) | 2005-03-01 |
WO2004100956A1 (en) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0419067A (pt) | método para aumento da cognição utilizando ziprasidona | |
MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
TN2009000242A1 (en) | Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | |
MY148982A (en) | Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals | |
MA34922B1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
TNSN07148A1 (en) | (biphenyl) carboxylic acids and derivatives thereof | |
EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
WO2007095050A3 (en) | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | |
BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
MA32323B1 (fr) | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques | |
EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
BRPI0509512A (pt) | método de tratar esquizofrenia e/ou anormalidades glicorregulatórias | |
MX2010006647A (es) | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
MA30592B1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
MA32108B1 (fr) | Derives d'indazole | |
BR0011403A (pt) | Processos para a purificação e para a preparação de ácido acrìlico ou ácido metacrìlico | |
ATE357453T1 (de) | Comt-inhibitoren | |
BRPI0713381A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de uma doença | |
MA28340A1 (fr) | Derives de l'acide 7- amino-4- quinolone-3-carboxylique substitues par un groupe cycloalkyle, methode pour leur production et leur utilisation en tant que medicaments | |
TW200500349A (en) | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
BRPI0408248A (pt) | derivados azabicìclicos de piridiloximetila e de benzisoxazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 3A. E 6A. ANUIDADES. |
|
B08J | Incorrect entry in the gazette republished [chapter 8.10 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2082 DE 30/11/2010. TEXTO CORRETO: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2082 DE 30/11/2010 E RPI 2090 DE 25/01/2011. |